We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Epizyme, Inc. (“Epizyme” or the “Company”) (NASDAQ:EPZM), in connection with the proposed acquisition of the Company by Ipsen S.A.(Euronext: IPN; ADR: IPSEY) via tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $1.45 in cash, plus one contingent value right (CVR) for each share of Epizyme common stock owned.

Weiss Law is investigating whether (i) Epizyme’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $1.45 per-share merger consideration adequately compensates Epizyme’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $5.00 median price target set by analysts, and at least one analyst set a price target for the Company of $8 per share, $6.55 above the per-share merger consideration.